Penn Medicine Provider
Pathology and Laboratory Medicine
Andrew David Fesnak, MD
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP

About me

  • Associate Professor of Clinical Pathology and Laboratory Medicine

Education and training

  • Medical School: University of Medicine and Dentistry of New Jersey
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Hospital of the University of Pennsylvania

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Fesnak is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Petrella J, Dai A, Mackey S, Correa A, Brennan AL, Fesnak A, Siegel D, Plesa G Feasibility of Releasing Fresh CART Cell Products for Infusion Based On Studying Product Post-Harvest Stability , Cytotherapy, 27(5): 2025,2


Fesnak, A T Cell and Related Immunotherapies , Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects: 2024


Fesnak, A Gene Therapy , Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects: 2024


Mack EA, Dougher MC, Ginda AM, Cahill C, Murter M, Schell K, Tanhehco YC, Bhoj VG, Fesnak AD, Siegel DL, Kambayashi T, Aqui NA, O'Doherty U Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis , Blood, 143(11): 2024,1049-1054


Mackey S, Dai A, Davis MM, Fesnak A, Siegel D, Plesa G Flow Cytometry Case Studies Illustrating Comprehensive Approach Required For Developing, Optimizing, And Implementing Multicolor Panels For The Manufacturing And Release Of Investigational Cell Therapy Products At UPenn , Cytotherapy, 26(6): 2024,S137-S138


Wang K, Tseng CY, Li Z, White C, Wang B, Levine BL, Fesnak AD A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy , Cytotherapy, 25(12): 2023,1370-1379


Plesa G, Brennan AL, Levine JR, Hasenmayer D, Buchholz K, Migliaccio T, Holland D, Colligon TA, Mackey S, Dai A, Petrella J, Ngo S, Fesnak A, Davis MM, Siegel D Multiple Efficiencies Gained by Implementing a Significantly Shorter Manufacturing Schedule for Production of CAR T Cell Products , Cytotherapy, 25(6): 2023,S9


Mackey, S., Dai, A., Gong, N., McGettigan, B., Jefferson, P., Petrella, J., Gohil, M., Fesnak, A., Siegel, D., Davis, M. M., Plesa, G. Developing and Optimizing Multicolor Flow Cytometry Methods for the Manufacturing and Release of 3-Day HuCART Products , Cytotherapy, 25(6): 2023,S189-S190


Fesnak AD, Raval JS Adverse Events of Cellular and Biotherapies , AABB Technical Manual, 21st edition: 2023


Fesnak AD, Siegel DL Chimeric antigen receptor T cells and other cellular immunotherapies , Rossi's Principles of Transfusion Medicine, Sixth Edition: 2022


View all publications